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Abstract
Introduction: Advanced glycation end products (AGEs) are produced and can accumulate during chronic
inflammation, as might be present in patients with rheumatoid arthritis (RA). AGEs are involved in the development
of cardiovascular disease. The aim of this study is to evaluate whether AGEs are increased in patients with long-
standing RA and whether AGE accumulation is related to disease activity, disease severity and measures of
(premature) atherosclerosis, such as endothelial activation, endothelial dysfunction and intima media thickness
(IMT).
Methods: In a cross-sectional study, 49 consecutive RA patients with longstanding disease (median disease
duration of 12.3 years (range 9.3 to 15.1)), receiving standard of care, were included and compared with 49 age-
and sex-matched healthy controls (HC). AGEs were determined by skin autofluorescence. Disease activity was
evaluated by the Disease Activity Score of 28 joints (DAS-28) score and joint damage by modified Sharp-v.d. Heijde
score. Endothelial activation (soluble vascular cellular adhesion molecule-1) sVCAM-1, von Willebrand factor (vWF),
thrombomodulin), endothelial dysfunction (determined by small artery elasticity (SAE)) and IMT were measured and
related to AGE accumulation.
Results: AGEs were increased in RA patients (median 2.4 arbitrary units (a.u.), range 1.6 to 4.2) compared to HC
(2.2, 1.3 to 3.8). RA patients had a DAS-28 score of 2.9 (0.8 to 6.9) and a modified Sharp-v.d. Heijde score of 19 (0
to 103). sVCAM-1 and vWF levels were higher in RA patients. SAE was significantly decreased in RA (3.9 ml/mmHg
(1.4 to 12.2) vs. 6.1 in HC (1.7 to 12.9). IMT did not differ between the two groups. Combining both groups’ AGEs
correlated with vWF, sVCAM-1 and IMT, and was inversely related to SAE. In RA, AGEs had an inverse relation with
SAE, but did not relate to disease activity or radiological damage. In multivariate analysis for both groups, smoking,
glucose levels, vWF, SAE and male gender were significantly related to the formation of AGEs.
Conclusions: AGEs were increased in RA patients with long-standing disease and without signs of premature
atherosclerosis. AGEs were related to endothelial activation and endothelial dysfunction. This supports the
hypothesis that in RA AGEs may be an early marker of cardiovascular disease.
Keywords: rheumatoid arthritis, endothelial cell activation, endothelial dysfunction, intima media thickness,
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Rheumatoid arthritis (RA) is associated with an excess
morbidity and mortality due to cardiovascular disease
(CVD). In a recent study, the risk for development of
cardiovascular disease in RA was comparable with that
in diabetics [1]. The excess in morbidity and mortality
in RA patients due to CVD cannot be explained by tra-
ditional risk factors alone [2]. One of the non-traditional
r i s kf a c t o r si n v o l v e di np a t i e n t sw i t hR Ai sc o n s i d e r e d
to be chronic inflammation [3].
Chronic inflammation is supposed to accelerate the
formation of the atherosclerotic plaque [4-6]. Inflamma-
tion results in endothelial activation and dysfunction,
which are considered to be the first steps in the process
finally resulting in atherosclerosis [7,8]. Endothelial cell
activation is characterized by up-regulation and release
of adhesion molecules, such as von Willebrand Factor
(vWF), soluble vascular cell adhesion molecule-1
(sVCAM-1) and thrombomodulin (TM). Endothelial cell
activation is followed by endothelial cell dysfunction.
This phase is characterized by influx of inflammatory
cells into the intima of the vascular wall and movement
of smooth muscle cells out of the tunica media into the
intima. Mononuclear cells absorb lipoproteins, such as
oxidized LDL to form foam cells [6]. This process leads
to an increased “stiffness” of the arterial wall, which can
be measured by several methods, such as pulse wave
analysis (PWA). PWA is a non-invasive method in
which the elasticity of the radial artery is calculated by
tonometry of the radial artery. PWA has been proven a
valid method to identify endothelial dysfunction in RA
[8]. Measurement of intima media thickness (IMT)
serves as a surrogate marker for atherosclerosis [9].
Chronic inflammation might result in the production
of advanced glycation end products (AGEs). Increased
levels of AGEs are correlated with the development of
future microvascular and macrovascular events in dia-
betics and non-diabetics [10-12]. AGEs can be quanti-
fied by a validated method that determines
autofluorescence in the skin [13] and are found in ather-
osclerotic plaques [14]. AGEs can also be measured in
plasma and urine. We deliberately chose measuring
AGEs in the skin because AGEs in the skin reflect oxi-
dative stress over a longer period of time compared to
AGEs in plasma and urine, which reflect a more acute
phase of oxidative stress. In a study in SLE patients,
AGEs in the skin proved to be elevated in contrast to
AGEs in plasma, which were not elevated [15]. AGEs
a r ef o r m e db yc r o s s - l i n k i n gof proteins, nucleic acids
and lipids [16] and can be a ligand for the receptor of
AGE (RAGE), which is expressed on neutrophils,
macrophages, T-cells and synovial fibroblasts [17].
Other known ligands for RAGE are, for example,
HMGB1 and S100A12. Higher levels of HMGB1 are
found in RA and predict mortality after myocardial
infarction [18,19]. Increased levels of S100A12 are corre-
lated with higher mortality in dialysis patients [20]. Liga-
tion of AGE to RAGE results in NF-B migration to the
nucleus, stimulates transcription of pro-inflammatory
genes and leads to up-regulation of endothelial adhesion
molecules, such as sVCAM-1. sVCAM-1 expression
facilitates adhesion of circulating T-lymphocytes [21].
As such, AGE-RAGE interaction can become a self-
maintaining process, contributing to the development of
atherosclerosis [22,23]. In RA, AGEs can be generated
as a result of oxidative stress during inflammation.
We hypothesize that in longstanding RA, AGEs are
increased due to prolonged exposure to oxidative stress
and that AGE accumulation is related to endothelial
activation, small artery elasticity and IMT, and to mar-
kers of disease damage. As such, AGEs might serve as a
measure of cumulative inflammation and might be a
predictor for CVD in RA patients.
Materials and methods
Patients and controls
Consecutive patients fulfilling the American College of
Rheumatology (ACR) criteria for RA and having a dis-
ease duration of at least 9 years with a maximum of 15
years, who attended the outpatient clinic of the Univer-
sity Medical Center Groningen, were asked to partici-
pate in this study.
Exclusion criteria were pregnancy, diabetes mellitus
(fasting blood glucose ≥7.0 mmol/L or the use of anti-
diabetic medications), renal impairment (serum creati-
nine > 140 μmol/L), surgery, myocardial infarction or
sepsis in the past three months. Fifty patients were
included. In addition, age- and sex-matched healthy
volunteers were recruited as controls. After inclusion
one patient declined further participation for personal
reasons. The matched control was, therefore, also
removed from further analysis.
Information was obtained from all subjects regarding
traditional cardiovascular risk factors, including body
mass index (BMI), smoking, blood pressure and lipid
levels. Hypertension was defined as systolic blood pres-
sure above 140 mmHg and/or a diastolic blood pres-
sure above 90 mmHg and/or current use of
antihypertensive drugs. Dyslipidaemia was defined as
plasma cholesterol above 6.21 mmol/L, plasma LDL
cholesterol above 3.36 mmol/L, plasma triglycerides
above 2.26 mmol/L or current use of lipid lowering
drugs. The study was approved by the local medical
ethics committee of the University Medical Center of
Groningen and informed consent was obtained from
all study participants.
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After an overnight fast, blood was sampled and creati-
nine, total cholesterol, triglycerides, high density lipo-
protein (HDL), low density lipoprotein (LDL), C-reactive
protein (CRP), erythrocyte sedimentation rate (ESR) and
glucose were measured routinely. Additionally, serum
and plasma samples were stored at -20°C for determina-
tion of endothelial cell activation markers. Serum levels
of sVCAM-1 and thrombomodulin were measured by
ELISA according to the manufacturer’s instructions
(R&D Systems, Abingdon, UK). Levels of vWF were
determined using in-house ELISA as described [24].
Measurement of disease activity
Disease activity was assessed using the Disease Activity
Score for 28 joints (DAS-28 score) [25,26]. Ranges of
DAS-28 correspond with disease activity. DAS-28 score
< 2.6 indicates remission. DAS-28 score 2.6 to 3.2 indi-
cates low disease activity. DAS-28 score 3.2 to 5.1 indi-
cates moderate disease activity. DAS-28 score above 5.1
is considered high disease activity. Besides the DAS-28,
for each patient the ACR/EULAR (American College of
Rheumatology/European League Against Rheumatism)
2010 criteria for remission were determined. In these
criteria patients are considered to be in remission if they
have a maximum of 1 for each of the following: 28-joint
count for swollen joints (SJC28) and tender joints
(TJC28), CRP (mg/dl) and patient’s global assessment (0
to 10 scale) [27].
Measurement of functional disability
Traditionally, disability was assessed using the Health
Assessment Questionnaire (HAQ), a score by question-
naire that examines the disabilities that RA-patients
encounter in daily living and activities [11]. The final
HAQ index ranges from 0 to 3. Although the mean
HAQ of the population rises with age, HAQ scores <
0.3 are considered normal [28].
Measurement of joint damage and cumulative CRP
To determine the amount of joint damage, we used the
van der Heijde modification of the Sharp score. The max-
imum erosion score for the hands is 160 and for the feet
120; the maximum score for joint space narrowing is 120
for the hands and 48 for the feet, resulting in a maximum
total score of 448 [29]. Radiography of the hands and feet
were performed when recent radiographs, taken within
one year, were not available. Cumulative CRP was calcu-
lated by calculating the area under the curve (AUC) by
using the trapezoid model [30].
Measurement of small artery elasticity
After overnight fasting, arterial elasticity was assessed
using the CR-2000 (Hypertension Diagnostics, Eagan, MN,
USA) for Pulse-Wave Analysis (PWA). The CR-2000
records and analyzes the blood pressure waveforms data
from the Arterial Pulse Pressure Sensor. The distal elasti-
city of the small arteries (SAE) was estimated from a com-
puterized pulse contour analysis [31,32]. The average of
three readings of these parameters taken over 15 minutes
was used. These measurements were performed on both
the right and left radial artery. The average of the three
measurements on each side were taken together and
divided by two. Blood pressure was recorded as the aver-
age of three measurements on both arms by placing a
blood pressure cuff on the opposite arm. Subjects lay in
the supine position. For analysis, we used the mean systo-
lic and diastolic blood pressure of these measurements.
Measurement of intima-media thickness
Details of the method have been described by de Groot
et al. [33]. In short, the IMT was determined in the far
wall segments of the common carotid artery, carotid
bulb and the internal carotid artery. A B-mode image of
these segments was obtained from a lateral transducer
position, during which the probe was positioned perpen-
dicular to the far wall, showing an intima-media com-
plex over approximately 1 cm. Subjects lay in the supine
position. Mean IMT (the mean of the measurements in
a segment) and maximum IMT (the highest IMT value
found among the segment studied) per segment were
calculated. Means of the mean IMT and means of the
maximum IMT were calculated as the average for the
six carotid segments of the mean value, and of the max-
imum value per segment, respectively. IMT was mea-
sured in a standardized way by the same experienced
technicians. Coefficient of variation of IMT measure-
ment of the GCA is approximately 5% [34].
AGE measurement
AGEs were measured by using the auto-fluorescence
reader (AGE-reader type 214B00102, DiagnOptics BV
Groningen, The Netherlands, patent PCT/NL99/00607).
The autofluorescence reader illuminates a skin surface of
4c m
2. Emission and excitation light from the skin are
measured with a spectrometer. Patients and healthy con-
trols were placed in a seated position and the reader was
placed 10 cm below the elbow fold at the volar side. Auto-
fluorescence is then calculated by dividing the average
emitted light intensity per nanometer in the range of 420
to 600 nm by the average emitted light in the range of 300
to 420 nm [35]. When patients have visible sunburn no
AGE measurement will be performed because of the fact
that AGE values are falsely elevated in sunburned skin.
Statistical methods
Data are expressed as median (range) unless stated
otherwise. The sample size of 50 patients was calculated
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AGE level between RA and HC with a power of 80%,
based on data from an earlier study by Lutgers et al.i n
diabetics [36]. Two-sample t-tests or Mann-Whitney-U
tests were used as appropriate to make comparisons
between patients and controls for continuous variables.
For categorical variables the chi-square method and for
very small expected frequencies the Fisher’s exact test
were used. Gaussian distribution of the data was ana-
lyzed with the D’Agostino-Pearson omnibus normality
test. Correlation analysis was performed by Pearson cor-
relation when variables were distributed normally; other-
wise the Spearman correlation was used. Predictor
analysis for AGE accumulation was performed using
multivariate linear regression with forward inclusion of
variables with P < 0.10 in univariate analysis. The prob-
ability of F for entry was 0.05, which means that vari-
ables were included until the P-value of the model did
not improve anymore. Analyses were performed using
Graphpad version 4.03 2005 (GraphPad Software, San
Diego, California, USA) and SPSS version 14.0 (SPSS
inc., Chicago, Illinois, USA). Two-sided P-values < 0.05
were considered significant.
Results
Clinical characteristics of patients and controls
Fifty RA patients and 50 healthy controls (HC) were
included. One patient withdrew for personal reasons;
subsequently, the matched control was excluded from
analysis. Characteristics of patients and controls, includ-
ing traditional cardiovascular risk factors, are shown in
Table 1. RA patients had a less favorable cardiovascular
risk profile: hypertension was more frequent in RA
patients compared to HC. Both systolic and diastolic
blood pressure were higher in patients. Furthermore,
BMI and the percentage of active smokers were higher
in the RA group. Although the proportion of individuals
with dyslipidemia did not differ between RA and HC,
absolute levels of HDL were lower and triglycerides
were higher in RA patients (Table 1).
Disease characteristics of the RA patients are shown in
Table 2. Disease activity as measured by DAS-28 score
indicated generally minor disease activity, with normal
distribution in D’Agostino and Pearson normality test.
(median 2.9, range 0.8 to 6.9) and the modified Sharp-v.
d. Heijde score was low (19 (0 to 103)) and was not nor-
mally distributed. Most RA patients were on disease-
modifying antirheumatic drug (DMARD) therapy, the
majority (63%) on methotrexate.
AGEs, endothelial cell activation, endothelial dysfunction
and intima media thickness
AGEs were increased (median 2.4 a.u., range 1.6 to 4.2)
in this group of RA patients with longstanding disease
in comparison to age- and sex-matched healthy controls
( 2 . 2a . u . ,r a n g e1 . 3t o3 . 8 )( F i g u r e1 ) .E n d o t h e l i a lc e l l
activation markers were increased in RA as well:
sVCAM-1 (491 (range 274 to 909) vs. 354 ng/ml (range
224 to 691) in HC), vWF (154 (range 49 to 603) vs. 97
ng/ml (range 22 to 298) in HC) and thrombomodulin
(8.5 (range 1 to 77) vs. 3.6 (range 1 to 32) ng/ml in HC)
were all significantly elevated in patients (Figure 2).
Endothelial dysfunction was present in RA as
Table 1 Baseline characteristics of patients and controls
RA patients
N=4 9
Controls
N=4 9
P-
value
Age (years) 58 (31 to 74) 59 (29 to 75) NS
Female (%) 61% 61% NS
Hypertension (%) 42% 16% 0.012
Systolic blood pressure
(mmHg)
140 (100 to
184)
130 (103 to
157)
0.016
Diastolic blood pressure
(mmHg)
79 (55 to 113) 72 (60 to 96) 0.038
Body mass index (kg/m2) 26.6 (18.4 to
49.7)
24.5 (18.9 to
31.6)
0.002
Glucose (mmol/L) 5.3 (4.0 to 6.2) 5.2 (4.3 to 6.9) NS
Creatinine (μmol/L) 73 (41 to 122) 71 (53 to 124) NS
Dyslipidemia (%) 37% 35% NS
Total cholesterol (mmol/L) 5.1 (2.9 to 7.1) 5.0 (2.4 to 6.8) NS
High density lipoprotein
(mmol/L)
1.4 (0.9 to 2.6) 1.7 (0.9 to 3.0) 0.004
Low density lipoprotein
(mmol/L)
3.1 (1.6 to 5.3) 3.2 (1.6 to 4.9) NS
Triglycerids (mmol/L) 1.14 (0.53 to
3.38)
0.95 (0.39 to
4.36)
0.047
Active smoking (%) 24% 10% 0.044
Hypertension was defined as: systolic blood pressure > 140 mmHg, diastolic
blood pressure > 90 mmHg or use of antihypertensive drugs. Dyslipidemia
was defined as: total cholesterol > 6.2 mmol/l, low density lipoprotein > 3.2
mmol/L, triglycerides > 2.26 mmol/L or use of lipid lowering drugs. All data
are represented as median with range.
Table 2 Patient characteristics of 49 patients with RA
Disease duration (years) 12.3 (9.3 to 15.1) yrs.
Reumatoid factor positive (%) 100%
Anti-CCP positive 79%
DAS-28 2.92 (0.75 to 6.9)
Remission (ACR/EULAR 2010 criteria) 18%
HAQ score 0.18 (0.0 to 1.45)
Sharp van der Heijde score 19 (0 to 103)
Medication MTX (63%)
SSZ (16%)
Anti-TNF (22%)
Rituximab (2%)
Leflunomide (6%)
Azathioprine (3%)
None (10%)
Disease duration in years. DAS-28 scores were normally distributed. HAQ and
Sharp van der Heijde scores were not normally distributed.
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12.2) in patients vs. 6.1 (range 1.7 to 12.9) ml/mmHg in
HC. In contrast, IMT did not differ between RA patients
and HC (0.75 (range 0.28 to 1.80) vs. 0.70 mm (range
0.49 to 1.46) in HC) (Figure 2).
Additionally, in the total group (RA and HC) univari-
ate analysis was performed (Table 3). AGE accumulation
was not significantly related to the presence of RA (P =
0 . 0 6 )b u td i ds h o was i g n i f i c a n ta s s o c i a t i o nw i t hs m o k -
ing, creatinine, male gender, glucose, age, HDL choles-
terol, triglycerides, systolic blood pressure, vWF and
IMT. Furthermore, AGE accumulation was inversely
related with SAE. In RA patients no correlation was
found between AGEs and DAS-28 score, Sharp-vd
Heijde score or cumulative CRP. In this group of 49 RA
patients, also, no correlation was found between AGEs
and markers of endothelial activation or IMT. However,
in RA patients AGEs did show an inverse relation with
SAE (Figure 3).
Multivariate analysis
In multivariate analysis with forward inclusion of vari-
ables with P < 0.10 as found in univariate analysis and F
for entry 0.05, smoking, male gender, glucose level, vWF
and SAE proved to be significant factors contributing to
the formation of AGEs. (Table 3). The adjusted R square
of this model was 0.481.
Discussion
Premature atherosclerosis has been shown to be
increased in RA [3,37,38]. Moreover, the presence of RA
seems to be an independent risk factor for the develop-
ment of CVD, equal to diabetes mellitus or smoking [1].
The key underlying mechanism is supposed to be the
presence of chronic inflammation [6]. As chronic
inflammation is represented by the accumulation of
AGEs and AGEs contribute to the atherosclerotic pro-
cess by themselves, in the current study we analyzed
whether AGE accumulation occurs in RA patients with
longstanding disease and whether AGE accumulation is
related to markers of (premature) atherosclerosis and
disease characteristics. In accordance with our findings
in patients with other systemic autoimmune diseases
[39,40], we found increased AGEs levels, as measured by
skin auto-fluorescence, in RA patients.
AGEs are generated under the influence of oxidative
stress as present in chronic inflammatory diseases like
RA. By activating the receptor for AGE (RAGE), translo-
cation of NF-B to the nucleus is enhanced. In the
nucleus, NF-B facilitates the transcription of pro-
inflammatory genes, finally resulting in, for example, the
up-regulation of sVCAM-1. In this way a positive feed-
back loop of AGE-RAGE interaction is established,
maintaining an inflammatory status in which AGEs can
be formed [17,21,41].
We found that AGEs were inversely related to SAE
and positively related to IMT, suggesting that AGEs are
involved in the formation of atherosclerotic plaques in
RA. The process of atherosclerosis is assumed to start
with endothelial activation [5]. Indeed, and in accor-
dance with the results found by others, endothelial acti-
vation was increased in our patients, reflected by
elevated sVCAM-1, vWF and thrombomodulin serum
levels [42,43]. In addition, endothelial dysfunction, con-
sidered to be the next step in the atherosclerotic pro-
cess, was present as shown by reduced SAE.
Although endothelial activation and endothelial cell
dysfunction were present in our RA patients, IMT was
not increased. Other studies, however, did find an
increase in IMT in RA [44-50]. First, this discrepancy
might be explained by differences in disease activity. In
contrast to the patients included in our study, who had
low disease activity (median DAS-28 of 2.92), the
patients in the studies by Hannawi, Daza and Georgia-
dis had more active disease, represented by much
higher DAS-28 scores of 4.39 (mean), 4.77 (median)
and 5.8 (mean), respectively. During moderate to high
disease activity edema of the vascular wall might be
present. Therefore, it is possible that in patients with
active RA and systemic inflammation, IMT not only
reflects the presence of atherosclerotic plaques but also
thickening of the intima media due to edema, leading
to an overestimation of the IMT. Indeed, during fol-
low-up Georgiadis et al. could demonstrate a reduction
of IMT in RA patients, associated with a decrease in
disease activity [45]. Also, in RA patients in remission
(DAS-28 score below 2.60) with an average disease
duration of three years, coronary artery disease was
not increased compared to controls [51]. Secondly,
Figure 1 AGE accumulation is significantly increased in RA
patients in comparison to healthy controls. The horizontal line
denotes the median.
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patient selection.
The RA patients included in this study, who were
selected solely for having a long disease duration, are
representative of our RA cohort and had increased pre-
valence of several traditional risk factors. This has been
shown by others as well [48]. In particular, smoking is
known as a risk factor not only for atherosclerosis, but
Figure 2 Endothelial activation markers (sVCAM-1, vWF, thrombomodulin), endothelial dysfunction (SAE) and IMT in RA and HC.
sVCAM-1, panel A. vWF, panel B. thrombomodulin panel C. SAE, panel D. IMT panel E. Horizontal lines denote the median.
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tors for CVD, only smoking attributed to the accumula-
tion of AGEs in multivariate analysis. In contrast to
what might be expected, hypertension, BMI and dyslipi-
demia were not related to AGE accumulation.
Although AGEs were increased in our RA patients,
factors other than the presence of RA seem to be
more responsible for AGE accumulation. Multivariate
analysis revealed that AGE accumulation was indepen-
dently related to smoking, male gender, glucose level
and serum vWF. In a study of 93 RA patients with a
mean age of 61 years, AGEs proved to be increased
compared to HC and osteoarthritis patients. In that
study there was no correlation between AGE accumu-
lation and severity of joint destruction, although there
was a tendency to higher AGEs in more severe
destructive disease [53]. We also did not find a rela-
tion between AGEs and disease severity, probably
because joint damage in our cohort was quite low,
indicating that RA patients in our cohort experienced
low disease activity throughout the course of the dis-
ease. In a study with etanercept, in 22 RA patients
with a mean disease duration of 15.3 years a signifi-
cant reduction in serum and urinary levels of pentosi-
dine (a sensitive marker for AGEs) was found after six
months of treatment with etanercept. In this study,
examining patients with high disease activity, a rela-
tion with decline in disease activity and pentosidine
levels was found, indicating that disease activity is
related to AGE formation [54]. In other auto-immune
diseases, such as SLE, disease duration of more than
10 years was an independent predictor of AGE accu-
mulation in the skin [39]. We speculate that in the RA
patients included in the present study, low inflamma-
tory activity throughout thec o u r s eo ft h ed i s e a s en o t
only hampered occurrence of joint damage but also
resulted in low production of AGEs and prevented an
increase in IMT. Whether the presence of RA is an
important factor in AGE accumulation in more active
disease remains unclear and is the subject of future
research.
Table 3 Univariate and multiple linear regression analysis with AGEs as dependent variable.
Univariate analysis Multivariate analysis
B (95% C.I.) P-value B (95% C.I.) P-value
R.A. 0.187 (-0.010 to 0.384) 0.063
smoking 0.433 (0.194 to 0.672) 0.001 0.318 (0.120 to 0.516) 0.002
hypertension 0.135 (-0.069 to 0.339) 0.193
BMI 0.011 (-0.010 to 0.032) 0.304
dyslipidemia 0.124 (-0.084 to 0.331) 0.239
creatinin 0.011 (0.006 to 0.017) < 0.001
Male gender 0.451 (0.266 to 0.637) < 0.001 0.330 (0.262 to 0.508) < 0.001
glucose 0.430 (0.247 to 0.612) < 0.001 0.196 (0.022 to 0.370) 0.028
age 0.020 (0.011 to 0.028) < 0.001
total cholesterol - 0.021 (-0.123 to 0.082) 0.688
HDL-cholesterol - 0.315 (-0.536 to 0.094) 0.006
LDL-cholesterol - 0.016 (-0.135 to 0.102) 0.784
triglycerides 0.215 (0.056 to 0.374) 0.009
RR systolic 0.007 (0.001 to 0.012) 0.030
RR diastolic 0.010 (0.000 to 0.019) 0.046
vWF 0.003 (0.001 to 0.004) < 0.001 0.002 (0.001 to 0.003) 0.001
SAE - 0.069 (-0.105 to -0.034) < 0.001 - 0.035 (-0.069 to -0.002) 0.039
IMT 0.429 (0.136 to 0.722) 0.005
Univariate and multiple linear regression analysis in both RA and HC cohorts combined. Multiple linear regression analysis was performed with forward inclusion
of variables with P < 0.10 in univariate analysis. All data are represented as B with 95% confidence interval. The adjusted R-square of this model was 0.481.
Figure 3 Correlation between AGEs and SAE in RA.
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Our study shows increased AGE accumulation in RA
patients, in particular related to smoking, male sex, glu-
cose levels, endothelial activation and endothelial dys-
function. No relation was found between AGEs and
actual disease activity and joint damage. Importantly,
AGEs were inversely related to endothelial dysfunction
in patients without signs of premature atherosclerosis.
This supports the hypothesis that in RA AGEs may be
early markers of cardiovascular disease. If so, this might
open new therapeutic strategies with AGE breakers,
such as alagebrium, a compound that not only degrades
AGEs but also improves endothelial dysfunction in an
animal model [55].
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